Total
0
Shares
Apiam Animal Health (ASX:AHX) - Managing Director Chris Richards
Managing Director Chris Richards
Source: Apiam Animal Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Apiam Animal Health (AHX) is set to acquire the business assets of Golden Plains Animal Hospital and Smythesdale Animal Hospital for $2.1 million
  • Both are high-performance veterinary clinics in Bannockburn and Smythesdale, near Ballarat
  • The clinics provide services across a range of companion and livestock animals, and are expected to generate revenue of $2.85 million in FY21
  • Settlement of Golden Plains occurred on August 3 while settlement of Smythesdale is expected by the end of the month
  • Apiam was up 1.62 per cent on the market with shares trading at 94 cents at 1:07 pm AEST

Apiam Animal Health (AHX) is set to acquire the business assets of Golden Plains Animal Hospital and Smythesdale Animal Hospital for $2.1 million.

Both are high-performance veterinary clinics situated in Bannockburn and Smythesdale, near Ballarat.

These clinics provide veterinary services across a range of companion and livestock animals and are expected to generate revenue of $2.85 million in FY21.

Managing Director Chris Richards said the acquisitions represented an important milestone in expanding AHX’s market presence across the Greater Geelong and Ballarat area.

“These locations are currently among the fastest growing regions in Victoria,” Dr Richards said. “We see significant opportunity to capture market share and consolidate our existing operations, allowing us to achieve efficiencies and resourcing benefits.

“Demand for veterinary care throughout the area continues to accelerate rapidly and we see it as a significant market opportunity for Apiam in FY22.”

Settlement of the Golden Plains asset occurred on August 3 while settlement of Smythesdale is expected by the end of the month.

Apiam was up 1.62 per cent on the market with shares trading at 94 cents at 1:07 pm AEST.

AHX by the numbers
More From The Market Herald

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) secures new licences in Q3 amid revenue slump

ResApp Health (RAP) has released its quarterly activities report for the three months to the end of September 2021.

" Incannex Healthcare (ASX:IHL) lands ethics approval for psychedelic-based anxiety treatment trial

Incannex Healthcare (IHL) has spiked on the ASX today after landing important regulatory approvals to trial a psychedelic-based treatment for severe anxiety.

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in